Penfluridol


Concise Prescribing Info
Indications/Uses
Psychoses.
Dosage/Direction for Use
Adult : PO Initial: 20-60 mg/wk. Severe/resistant: ≤250 mg/wk.
Dosage Details
Oral
Psychoses
Adult: Initially, 20-60 mg wkly, increased up to 250 mg once a wk in severe or resistant conditions.
Contraindications
Preexisting CNS depression or coma.
Special Precautions
Pregnancy and lactation; elderly; epilepsy; preexisting cardiac conduction problems; hypokalaemia, hypomagnesemia; hypothyroidism.
Adverse Reactions
Lower threshold for seizures, blurring of vision, dry mouth, retention of urine, constipation, orthostatic hypotension, weight gain, impaired glucose tolerance, allergic skin rashes, cholestatic jaundice; extrapyramidal effects; delirium; agitation, anxiety, depression, euphoria; anorexia, constipation, diarrhoea; alopecia; amenorrhoea, hypoglycaemia; hyponatraemia; hypersalivation, nausea, vomiting; bronchospasm; reported increased risk of breast cancer.
Potentially Fatal: Blood dyscrasias; neuroleptic malignant syndrome; alteration of heart conduction leading to QT prolongation and life threatening arrhythmias.
Overdosage
Symptoms: deep sleep, dystonia, extrapyramidal symptoms. Treatment: supportive and symptom specific.
Drug Interactions
Orthostatic hypotension with MAOIs; may increase sedation with alcohol, hypnotics, antihistamines, opiates; antacids containing aluminum salts may decrease absorption; additive antimuscarinic effects with TCAs; may reduce bromocriptine's ability to reduce serum prolactin; amphetamines may increase psychosis; may inihibit antiparkinsonian effects of levodopa; may increase risk of extrapyrimidal symptoms with metoclopramide; may increase phenytoin levels (phenytoin may reduce penfluridol levels); possible additive effects on QT interval with type 1a antiarrhythmics, TCAs, some quinolone antibiotics (e.g. moxifloxacin), may have additive hypotensive effects with trazodone; may increase levels of valproic acid.
Potentially Fatal: May produce neurotoxicity with lithium.
Food Interaction
Avoid valerian, St John's wort, kava kava, gotu kola; increased risk of CNS depression.
Action
Description: Penfluridol blocks the postsynaptic dopamine receptor in the mesolimbic dopaminergic system and inhibits the release of hypothalamic and hypophyseal hormones.
Duration: 1 wk.
Pharmacokinetics:
Absorption: Absorbed from the GI tract (oral); peak plasma concentrations after 2 hr.
Metabolism: Undergoes enterohepatic recycling.
Excretion: Urine and faeces (as N-dealkylated metabolite). Elimination half-life: 36 hr (initial), 120 hr (terminal).
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Penfluridol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in